VE607 Binding to Spike Protein RBD Blocks SARS-CoV-2 Entry
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for therapies that effectively prevent or treat SARS-CoV-2 infections, including variants, while minimizing the risk of viral escape from natural or vaccine-induced immunity.
Innovation Solution
The use of 3,3′-(1,3-phenylenebis(oxy))bis(1-(piperidin-1-yl)propan-2-ol) (VE607) or its pharmaceutically acceptable salts to prevent or treat SARS-CoV-2 infections by blocking the entry of the virus into ACE2-expressing cells, effective against various SARS-CoV-2 variants.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies targeting SARS-CoV-2 are used, then viral infection can be prevented or treated to some extent, but the risk of viral escape from natural or vaccine-induced immunity remains high
Solution Approach 1:
The patent modifies the chemical structure of VE607 by changing physical or chemical parameters (such as molecular weight, functional groups, or stereochemistry) to create derivatives with enhanced binding affinity to the Spike protein RBD. This parameter change allows the compound to maintain effectiveness against SARS-CoV-2 while reducing the likelihood of viral escape mutations.
Solution Approach 2:
The patent combines VE607 with other compounds or molecules to create a composite therapeutic formulation. This combination approach enhances the overall effectiveness of the therapy while providing cross-protection against viral variants, thereby reducing the risk of viral escape from immunity.
2Reliability
If VE607 binds to the receptor-binding domain of the Spike protein, then viral entry into ACE2-expressing cells is blocked, but the compound must achieve high binding affinity to be effective against variants
Solution Approach 1:
The patent optimizes the binding affinity parameter of VE607 by modifying its chemical structure. This includes adjusting molecular weight, introducing functional groups that enhance interaction with the RBD, or changing stereochemical configurations to achieve high-affinity binding across different SARS-CoV-2 variants.
Solution Approach 2:
The patent designs VE607 and its derivatives to perform multiple functions: binding to the RBD of various Spike protein variants, blocking viral entry, and maintaining effectiveness across different SARS-CoV-2 strains. This universal binding capability ensures reliable viral entry blocking without requiring variant-specific compounds.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
VE607 demonstrates the ability to inhibit SARS-CoV-2, including variants such as Delta and Omicron, by binding to the receptor-binding domain of the Spike protein, thereby reducing the risk of infection and potentially overcoming vaccine evasion.
Implementation Method 1
VE607 demonstrates the ability to inhibit SARS-CoV-2, including variants such as Delta and Omicron, by binding to the receptor-binding domain of the Spike protein
Data Source
AI summary
The present application relates to the use of 3,3′-(1,3-phenylenebis(oxy))bis(1-(piperidin-1-yl)propan-2-ol (VE607) or a pharmaceutically acceptable salt thereof for the inhibition of SARS-CoV-2 and/or management of COVID-19.